Skip to main content
. 2017 Oct 13;8(6):1309–1318. doi: 10.1007/s13300-017-0315-y

Table 1.

Patient characteristics at baseline by group

Parameter Group 1 (n = 43) Group 2 (n = 35) Group 3 (n = 38)
T2DM, n (%) 31 (72.1%) 26 (74.3%) 31 (81.6%)
Age, years 53.1 ± 13.3 53.4 ± 12.6 54.3 ± 12.1
Diabetes duration, years 9.8 ± 7.0 8.8 ± 7.0 8.3 ± 5.4
Duration of insulin use, years 5.9 ± 3.8 5.1 ± 3.4 4.8 ± 3.0
A1C, % (mmol/mol) 8.7 ± 1.4 (72) 8.5 ± 1.7 (69) 8.8 ± 1.9 (73)
A1C > 9%, n (%) 17 (39.3) 12 (34.2) 15 (39.4)
FPG, mmol/L 9.5 ± 3.9 10.2 ± 3.8 9.6 ± 3.9
BMI, kg/m2 31.9 ± 8.4 32.9 ± 10.2 32.4 ± 8
Injection regions, n (%)
 Abdomen 29 (67.4) 30 (86.2) 32 (84.0)
 Abdomen/thigh 5 (12.6) 1 (2.8) 2 (5.7)
 Abdomen/thigh/buttock 0 0 1 (2.6)
 Abdomen/thigh/shoulder 5 (11.0) 0 3 (7.7)
Needle length, n (%)
 12.7 mm 4 (9.0) 4 (10.0) 5 (12.9)
 8 mm 32 (75.0) 29 (82.0) 29 (76.9)
 6 mm 1 (2.3) 1 (4.0) 2 (5.1)
 5 mm 16 (13.7) 1 (4.0) 2 (5.1)
Needle reuse, n (%)
 2–5 times 21 (48.8) 12 (34.3) 12 (31.5)
 6–10 times 12 (27.9) 13 (37.1) 19 (50.0)
 > 10 times 10 (23.3) 10 (28.6) 7 (18.4)
Injection site errors, n (%)
 Needle insertion < 5 s 13 (30.0) 10 (28.6) 16 (28.9)
 Rotation 14 (32.0) 7 (20.0) 11 (28.9)
 Insulin leakage after injection 6 (13.9) 2 (5.7) 5 (13.1)
Injection site pain, n (%) 12 (27.9) 4 (11.4) 8 (21.1)
Injection site bruising, n (%) 13 (30.2) 10 (28.6) 7 (18.4)
Lipodystrophy, n (%) 13 (30.0) 3 (8.5) 11 (28.9)

Numbers are mean ± SD, unless otherwise noted

A1C glycated hemoglobin, BMI body mass index, FPG fasting plasma glucose, T2DM type 2 diabetes mellitus